HK1097444A1 - Lactate salts of quinolinone compounds and their pharmaceutical use - Google Patents
Lactate salts of quinolinone compounds and their pharmaceutical useInfo
- Publication number
- HK1097444A1 HK1097444A1 HK07102634.1A HK07102634A HK1097444A1 HK 1097444 A1 HK1097444 A1 HK 1097444A1 HK 07102634 A HK07102634 A HK 07102634A HK 1097444 A1 HK1097444 A1 HK 1097444A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical use
- lactate salts
- quinolinone compounds
- quinolinone
- compounds
- Prior art date
Links
- 150000003893 lactate salts Chemical class 0.000 title 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51791503P | 2003-11-07 | 2003-11-07 | |
US52642503P | 2003-12-02 | 2003-12-02 | |
US52642603P | 2003-12-02 | 2003-12-02 | |
US54601704P | 2004-02-19 | 2004-02-19 | |
PCT/US2004/036941 WO2005046589A2 (en) | 2003-11-07 | 2004-11-05 | Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1097444A1 true HK1097444A1 (en) | 2007-06-29 |
Family
ID=34596121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07102634.1A HK1097444A1 (en) | 2003-11-07 | 2007-03-09 | Lactate salts of quinolinone compounds and their pharmaceutical use |
Country Status (15)
Country | Link |
---|---|
US (7) | US20050209247A1 (ko) |
EP (4) | EP1682529A4 (ko) |
JP (5) | JP4823914B2 (ko) |
KR (3) | KR101167573B1 (ko) |
CN (1) | CN102225926A (ko) |
AU (3) | AU2004289672C1 (ko) |
BR (1) | BRPI0416143A (ko) |
CA (3) | CA2543820C (ko) |
EA (1) | EA012621B1 (ko) |
ES (1) | ES2486240T3 (ko) |
HK (1) | HK1097444A1 (ko) |
IL (5) | IL174471A (ko) |
MX (1) | MXPA06004194A (ko) |
TW (1) | TWI347940B (ko) |
WO (3) | WO2005047244A2 (ko) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
ATE309996T1 (de) * | 2000-09-11 | 2005-12-15 | Chiron Corp | Chinolinonderivate als tyrosin-kinase inhibitoren |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
EP1565187A4 (en) * | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
ES2486240T3 (es) * | 2003-11-07 | 2014-08-18 | Novartis Ag | Sales de lactato de compuestos de quinolinona y su uso farmacéutico |
EP1718306A2 (en) * | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
WO2006081445A2 (en) * | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics Inc. | Treatment of metastasized tumors |
US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
TW200716136A (en) * | 2005-04-25 | 2007-05-01 | Genaera Corp | Polymorphic and amorphous salt forms of squalamine dilactate |
MX2007014206A (es) | 2005-05-13 | 2008-02-07 | Novartis Ag | Metodos para tratar cancer resistente a los farmacos. |
BRPI0610355A2 (pt) * | 2005-05-17 | 2010-06-15 | Novartis Ag | métodos par sintetizar compostos heterocìclicos |
AU2012258324B2 (en) * | 2005-05-17 | 2014-07-24 | Novartis Ag | Methods for synthesizing heterocyclic compounds |
RU2425041C2 (ru) | 2005-05-23 | 2011-07-27 | Новартис Аг | Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она |
EP1904065A2 (en) * | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
NZ567550A (en) * | 2005-11-29 | 2011-08-26 | Novartis Ag | Formulations of lactic acid salts of 4-amino-5-fluoro-3-[6-(4-methyl-piperazin-1-yl)-1 H-benzimidazol-2-yl]1H-quinolin-2-one |
CN101316593B (zh) * | 2005-11-29 | 2012-05-02 | 诺瓦提斯公司 | 喹啉酮类的制剂 |
EP1960547A2 (en) | 2005-12-08 | 2008-08-27 | Novartis AG | Effects of inhibitors of fgfr3 on gene transcription |
CN100488960C (zh) * | 2006-03-09 | 2009-05-20 | 中国药科大学 | 2-位取代的喹诺酮类化合物及其在制药中的应用 |
WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
CL2008000681A1 (es) * | 2007-03-09 | 2008-10-24 | Novartis Ag | Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona. |
CN101687840A (zh) | 2007-06-25 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 作为激酶抑制剂的苯并咪唑酰胺基衍生物 |
GB0800855D0 (en) | 2008-01-17 | 2008-02-27 | Syngenta Ltd | Herbicidal compounds |
JPWO2009113436A1 (ja) * | 2008-03-14 | 2011-07-21 | 国立大学法人 千葉大学 | Fgfr3遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法 |
AR070924A1 (es) * | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
WO2010059239A2 (en) * | 2008-11-21 | 2010-05-27 | Millennium Pharmaceuticals, Inc | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders |
EP2381779A4 (en) * | 2008-12-22 | 2012-10-24 | Sanford Burnham Med Res Inst | SELECTIVE ACT-INHIBITORS AND METHOD FOR THEIR USE |
KR20210151988A (ko) | 2009-01-16 | 2021-12-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
RU2012145468A (ru) * | 2010-03-26 | 2014-05-10 | Новартис Аг | Получение гидратированных полиморфов соли молочной кислоты 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она |
SG184311A1 (en) * | 2010-04-16 | 2012-11-29 | Novartis Ag | Combination of organic compounds |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
CN114209699A (zh) | 2010-07-16 | 2022-03-22 | 埃克塞里艾克西斯公司 | C-met调节剂药物组合物 |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
KR20210010671A (ko) | 2011-02-10 | 2021-01-27 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
EP2524915A1 (en) * | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
WO2013063003A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Method of treating gastrointestinal stromal tumors |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
WO2013088191A1 (en) | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
KR20140117457A (ko) | 2012-01-31 | 2014-10-07 | 노파르티스 아게 | Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도 |
PT2824181T (pt) | 2012-03-08 | 2018-12-20 | Astellas Pharma Inc | Novo produto de fusão de fgfr3 |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
EP2872142A1 (en) | 2012-07-11 | 2015-05-20 | Novartis AG | Method of treating gastrointestinal stromal tumors |
AU2013292054B2 (en) * | 2012-07-17 | 2017-08-03 | Sanofi | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma |
CN107501413A (zh) * | 2012-09-27 | 2017-12-22 | 中外制药株式会社 | Fgfr3融合基因和以其作为标靶的药物 |
WO2014058785A1 (en) | 2012-10-10 | 2014-04-17 | Novartis Ag | Combination therapy |
CN103804305A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
CA2897651C (en) | 2013-01-10 | 2021-09-21 | Pulmokine, Inc. | Non-selective kinase inhibitors |
EP3632426A1 (en) | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
KR102277833B1 (ko) | 2013-02-20 | 2021-07-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물 및 그의 용도 |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
CN111743901B (zh) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
MD4635C1 (ro) | 2013-10-14 | 2020-01-31 | Eisai R&D Management Co., Ltd. | Compuşi de chinolină substituiţi selectiv |
EP3057948B1 (en) | 2013-10-14 | 2018-03-14 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline derivatives |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US9458169B2 (en) | 2013-11-01 | 2016-10-04 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
DK3122359T3 (da) | 2014-03-26 | 2021-03-08 | Astex Therapeutics Ltd | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer |
EP2977374A1 (en) | 2014-07-21 | 2016-01-27 | Université de Strasbourg | Molecules presenting dual emission properties |
AU2015295405B2 (en) | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
WO2016139227A1 (en) | 2015-03-03 | 2016-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fgfr3 antagonists |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
AU2016328692B2 (en) | 2015-09-23 | 2021-03-11 | Janssen Pharmaceutica Nv | New compounds |
MX2018003564A (es) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer. |
JP6884973B2 (ja) * | 2015-10-23 | 2021-06-09 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 疼痛に対して活性を有するオキサジアザスピロ化合物 |
CN109400613B (zh) * | 2015-12-31 | 2021-05-07 | 上海医药集团股份有限公司 | 喹啉类化合物富马酸盐的晶型、制备方法、组合物与应用 |
RU2754858C2 (ru) * | 2016-01-11 | 2021-09-08 | Мерк Патент Гмбх | Производные хинолин-2-она в качестве ингибиторов киназы c-kit |
TWI590475B (zh) * | 2016-06-17 | 2017-07-01 | 財團法人工業技術研究院 | 堆疊型太陽能電池模組 |
WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CN107935858B (zh) * | 2016-10-12 | 2020-09-08 | 利尔化学股份有限公司 | 5-氟-2-硝基苯酚的制备方法 |
WO2018081567A1 (en) | 2016-10-27 | 2018-05-03 | Pulmokine, Inc. | Combination therapy for treating pulmonary hypertension |
EP3645526A4 (en) | 2017-06-27 | 2020-10-28 | Janssen Pharmaceutica NV | NEW QUINOLEINONE COMPOUNDS |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
JP7312171B2 (ja) | 2017-11-24 | 2023-07-20 | ヤンセン ファーマシューティカ エヌ.ベー. | ピラゾロピリジノン化合物 |
CN111655689B (zh) | 2017-11-24 | 2023-01-06 | 詹森药业有限公司 | 吡唑并吡啶酮化合物 |
JP2021532158A (ja) * | 2018-07-31 | 2021-11-25 | ザ、トラスティーズ オブ プリンストン ユニバーシティ | 転移性癌および化学療法抵抗性癌の治療のためのテトラヒドロキノリノ誘導体 |
AU2019413504A1 (en) * | 2018-12-26 | 2021-06-03 | Janssen Pharmaceutica Nv | Thienopyridinone compounds |
WO2023147513A2 (en) * | 2022-01-28 | 2023-08-03 | Washington University | Compositions of autophagy modulating agents and uses thereof |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663606A (en) * | 1966-06-21 | 1972-05-16 | Mitsui Toatsu Chemicals | Organic imino-compounds |
DE2363459A1 (de) | 1973-12-20 | 1975-06-26 | Basf Ag | Neue fluoreszierende chinolinverbindungen |
US4287341A (en) | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
US4659657A (en) * | 1982-12-24 | 1987-04-21 | Bayer Aktiengesellschaft | Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases |
DE3634066A1 (de) * | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
JPH0699497B2 (ja) | 1987-04-16 | 1994-12-07 | 富士写真フイルム株式会社 | 光重合性組成物 |
DE3932953A1 (de) * | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5151360A (en) * | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
GB9108547D0 (en) | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
USRE37650E1 (en) * | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5856115A (en) * | 1991-05-24 | 1999-01-05 | Fred Hutchinson Cancer Research Center | Assay for identification therapeutic agents |
DK0627940T3 (da) * | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
JP3142378B2 (ja) | 1992-06-22 | 2001-03-07 | ティーディーケイ株式会社 | 有機el素子 |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
US5792771A (en) * | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
US5763441A (en) * | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5981569A (en) * | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
JPH0743896A (ja) | 1993-07-28 | 1995-02-14 | Toyobo Co Ltd | 光重合性組成物 |
CN1118595A (zh) | 1993-12-27 | 1996-03-13 | 卫材株式会社 | 氨茴酸衍生物 |
JPH0829973A (ja) | 1994-07-11 | 1996-02-02 | Toyobo Co Ltd | 光重合性組成物 |
JP3441246B2 (ja) * | 1995-06-07 | 2003-08-25 | 富士写真フイルム株式会社 | 光重合性組成物 |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6010711A (en) * | 1996-01-26 | 2000-01-04 | University Of Rochester | Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors |
US6514971B1 (en) | 1996-03-15 | 2003-02-04 | Zeneca Limited | Cinnoline derivatives and use as medicine |
DE19610723A1 (de) | 1996-03-19 | 1997-09-25 | Bayer Ag | Elektrolumineszierende Anordnungen unter Verwendung von Blendsystemen |
US5942385A (en) * | 1996-03-21 | 1999-08-24 | Sugen, Inc. | Method for molecular diagnosis of tumor angiogenesis and metastasis |
AU3102697A (en) * | 1996-06-19 | 1998-01-07 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
BR9711805A (pt) | 1996-06-20 | 2002-01-15 | Regents The Univesity Of Texas | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos |
NZ334125A (en) * | 1996-09-25 | 2000-10-27 | Zeneca Ltd | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
US6111110A (en) * | 1996-10-30 | 2000-08-29 | Eli Lilly And Company | Synthesis of benzo[f]quinolinones |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
EP1005470B1 (en) | 1997-08-22 | 2007-08-01 | AstraZeneca AB | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
CA2328893A1 (en) | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Vegf activity inhibitors |
US6174912B1 (en) * | 1998-08-21 | 2001-01-16 | Dupont Pharmaceuticals Company | Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists |
DE19841985A1 (de) | 1998-09-03 | 2000-03-09 | Schering Ag | Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate |
IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
DE69935245T2 (de) * | 1998-12-04 | 2007-10-31 | Bristol-Myers Squibb Co. | 3-substituierte-4-arylchinolin-2-on derivate als kaliumkanal- modulatoren |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
KR100298572B1 (ko) * | 1999-08-19 | 2001-09-22 | 박찬구 | 카바아닐라이드로부터 4-니트로디페닐아민과 4-니트로소디페닐아민의 제조방법 |
ATE290865T1 (de) * | 1999-10-19 | 2005-04-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
KR100681724B1 (ko) * | 1999-10-19 | 2007-02-28 | 머크 앤드 캄파니 인코포레이티드 | 티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물 |
US7045133B2 (en) | 2000-01-18 | 2006-05-16 | Ludwig Institute For Cancer Research | VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
AU2001229254B2 (en) | 2000-01-19 | 2006-07-27 | Gill, Parkash S. | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
DE122008000002I1 (de) | 2000-02-15 | 2008-04-17 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
US6420382B2 (en) * | 2000-02-25 | 2002-07-16 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
JP2003523390A (ja) | 2000-02-25 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
US6313138B1 (en) * | 2000-02-25 | 2001-11-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PL202918B1 (pl) * | 2000-03-07 | 2009-08-31 | Rush Presbyterian St Luke | Przeciwbakteryjna i antykoncepcyjna kompozycja oraz jej zastosowanie |
US6257320B1 (en) * | 2000-03-28 | 2001-07-10 | Alec Wargo | Heat sink device for power semiconductors |
WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
ATE448226T1 (de) * | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
ATE309996T1 (de) * | 2000-09-11 | 2005-12-15 | Chiron Corp | Chinolinonderivate als tyrosin-kinase inhibitoren |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
EP1188751A1 (en) * | 2000-09-13 | 2002-03-20 | Casale Chemicals SA | Process for the production of high purity melamine from urea |
EP1401831A1 (en) * | 2001-07-03 | 2004-03-31 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
WO2003033472A1 (fr) * | 2001-10-17 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes |
US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
US20030159702A1 (en) * | 2002-01-21 | 2003-08-28 | Lindell Katarina E.A. | Formulation and use manufacture thereof |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
AU2003288899B2 (en) * | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
EP1545529A4 (en) * | 2002-09-30 | 2010-03-03 | Bristol Myers Squibb Co | NEW TYROSINE KINASE HEMMER |
EP1565187A4 (en) * | 2002-11-13 | 2010-02-17 | Novartis Vaccines & Diagnostic | CANCER TREATMENT METHODS AND RELATED METHODS |
US6774327B1 (en) * | 2003-09-24 | 2004-08-10 | Agilent Technologies, Inc. | Hermetic seals for electronic components |
US20070274981A1 (en) * | 2003-10-16 | 2007-11-29 | Imclone Systems Incorporation | Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof |
ES2486240T3 (es) * | 2003-11-07 | 2014-08-18 | Novartis Ag | Sales de lactato de compuestos de quinolinona y su uso farmacéutico |
EP1718306A2 (en) * | 2004-02-20 | 2006-11-08 | Chiron Corporation | Modulation of inflammatory and metastatic processes |
BRPI0613200A2 (pt) * | 2005-05-18 | 2012-01-03 | M & G Polimeri Italia Spa | composiÇço de poliÉster |
-
2004
- 2004-11-05 ES ES04816941.1T patent/ES2486240T3/es active Active
- 2004-11-05 BR BRPI0416143-2A patent/BRPI0416143A/pt not_active IP Right Cessation
- 2004-11-05 JP JP2006538512A patent/JP4823914B2/ja not_active Expired - Fee Related
- 2004-11-05 JP JP2006538526A patent/JP4724665B2/ja not_active Expired - Fee Related
- 2004-11-05 CA CA2543820A patent/CA2543820C/en not_active Expired - Fee Related
- 2004-11-05 CA CA002544186A patent/CA2544186A1/en not_active Abandoned
- 2004-11-05 US US10/982,543 patent/US20050209247A1/en not_active Abandoned
- 2004-11-05 AU AU2004289672A patent/AU2004289672C1/en not_active Ceased
- 2004-11-05 EP EP04810468A patent/EP1682529A4/en not_active Withdrawn
- 2004-11-05 EA EA200600928A patent/EA012621B1/ru not_active IP Right Cessation
- 2004-11-05 WO PCT/US2004/036956 patent/WO2005047244A2/en active Application Filing
- 2004-11-05 CN CN2011100963250A patent/CN102225926A/zh active Pending
- 2004-11-05 AU AU2004288709A patent/AU2004288709B2/en not_active Ceased
- 2004-11-05 WO PCT/US2004/037051 patent/WO2005046590A2/en active Application Filing
- 2004-11-05 EP EP04810419A patent/EP1692085A4/en not_active Withdrawn
- 2004-11-05 JP JP2006538509A patent/JP4890255B2/ja not_active Expired - Fee Related
- 2004-11-05 EP EP04816941.1A patent/EP1699421B1/en not_active Not-in-force
- 2004-11-05 CA CA2544492A patent/CA2544492C/en not_active Expired - Fee Related
- 2004-11-05 TW TW093133800A patent/TWI347940B/zh not_active IP Right Cessation
- 2004-11-05 KR KR1020067011003A patent/KR101167573B1/ko not_active IP Right Cessation
- 2004-11-05 KR KR1020067009999A patent/KR20060111520A/ko active IP Right Grant
- 2004-11-05 MX MXPA06004194A patent/MXPA06004194A/es active IP Right Grant
- 2004-11-05 EP EP14165975.5A patent/EP2762475A1/en not_active Withdrawn
- 2004-11-05 WO PCT/US2004/036941 patent/WO2005046589A2/en active Application Filing
- 2004-11-05 KR KR1020067007021A patent/KR101224410B1/ko not_active IP Right Cessation
- 2004-11-05 US US10/982,757 patent/US20050137399A1/en not_active Abandoned
-
2006
- 2006-03-22 IL IL174471A patent/IL174471A/en not_active IP Right Cessation
- 2006-04-04 IL IL174767A patent/IL174767A0/en unknown
- 2006-05-02 IL IL175385A patent/IL175385A/en not_active IP Right Cessation
-
2007
- 2007-03-09 HK HK07102634.1A patent/HK1097444A1/xx not_active IP Right Cessation
-
2009
- 2009-03-04 US US12/398,130 patent/US20090181979A1/en not_active Abandoned
-
2010
- 2010-11-18 JP JP2010258402A patent/JP2011042687A/ja not_active Withdrawn
-
2011
- 2011-05-16 AU AU2011202249A patent/AU2011202249B2/en not_active Ceased
- 2011-05-26 JP JP2011118515A patent/JP5214768B2/ja not_active Expired - Fee Related
- 2011-12-02 US US13/309,879 patent/US20130018058A1/en not_active Abandoned
- 2011-12-21 IL IL217114A patent/IL217114A/en not_active IP Right Cessation
-
2012
- 2012-05-16 IL IL219818A patent/IL219818A0/en unknown
- 2012-07-02 US US13/539,872 patent/US20120277434A1/en not_active Abandoned
-
2013
- 2013-08-01 US US13/956,463 patent/US20130338171A1/en not_active Abandoned
-
2014
- 2014-03-17 US US14/215,437 patent/US20140303182A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1097444A1 (en) | Lactate salts of quinolinone compounds and their pharmaceutical use | |
AP2037A (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
IL176248A0 (en) | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | |
CY2018005I1 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
IL170758A0 (en) | 7-amino-isoindolyl compounds and their pharmaceutical uses | |
IL186435A0 (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
LT3056492T (lt) | Meglumino druska ir atitinkamos vaisto (delafloksacino) kristalinės formos | |
IL184735A0 (en) | Pharmaceutical formulations and methods of use | |
HK1084949A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
EP1855531A4 (en) | METHOD FOR INCREASING THE ORAL BIOVERABILITY OF A MEDICAMENT AND COMPOSITIONS FROM LESS TOXIC OROTATE SALTS | |
IL185537A0 (en) | 7 - (2 - (4 - (3 - trifluoromethyl - phenyl) - 1, 2, 3, 6 - tetrahydro - pyrid - 1 - yl) ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof | |
PL1937407T3 (pl) | Roztwory bezwodnych soli lantanowców i ich otrzymywanie | |
PL1740204T3 (pl) | Lecznicze zastosowanie alfa-mannozydazy | |
SI1699421T1 (sl) | Laktatne soli kinolinonskih spojin in njihova farmacevtska uporaba | |
ZA200606065B (en) | Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies | |
HK1077572A1 (en) | Pharmaceutical salts of reboxetine | |
PL378197A1 (pl) | Pochodne kwasów indenokarboksylowych oraz ich zastosowanie do leczenia i zapobiegania cukrzycy i dyslipidemii | |
GB0315878D0 (en) | Aryl carboxylic acid derivatives and their therapeutic use | |
SI1699764T1 (sl) | Soli bis-dikarboksilne kisline benazeprila in priprava benazeprila preko teh soli | |
GB0322195D0 (en) | Compounds and their medical uses | |
GB0322194D0 (en) | Compounds and their medical uses | |
ZA200709485B (en) | Oral pharmaceutical formulations comprising fenofibric acid and/or its salts | |
GB0317519D0 (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases | |
GB0317497D0 (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases | |
GB0317515D0 (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: TESCONI, MARC, S |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181105 |